User profiles for Darrell Tan
 | Darrell TanDepartment of Infectious Diseases, St. Michael's Hospital Verified email at smh.ca Cited by 5892 |
[HTML][HTML] Monkeypox virus infection in humans across 16 countries—April–June 2022
…, AM Cattelan, K Makofane, D Tan… - … England Journal of …, 2022 - Mass Medical Soc
Background Before April 2022, monkeypox virus infection in humans was seldom reported
outside African regions where it is endemic. Currently, cases are occurring worldwide. …
outside African regions where it is endemic. Currently, cases are occurring worldwide. …
Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act
RW Burgoyne, DHS Tan - Journal of antimicrobial …, 2008 - academic.oup.com
Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS
have resulted in decreased morbidity and mortality. To some extent, the role of disease …
have resulted in decreased morbidity and mortality. To some extent, the role of disease …
Multidrug-resistant HIV-1 infection despite preexposure prophylaxis
…, PL Anderson, PR Harrigan, DHS Tan - New England Journal …, 2017 - Mass Medical Soc
… Darrell HS Tan, MD, Ph.D. … Knox DC, Anderson PL, Harrigan PR, Tan DHS. HIV-1 infection
with multi-class resistance despite pre-exposure prophylaxis (PrEP). Presented at the 23rd …
with multi-class resistance despite pre-exposure prophylaxis (PrEP). Presented at the 23rd …
Use of an HIV‐risk screening tool to identify optimal candidates for PrEP scale‐up among men who have sex with men in Toronto, Canada: disconnect between …
…, T Grennan, J Maxwell, DHS Tan - Journal of the …, 2016 - Wiley Online Library
Introduction Identifying appropriate pre‐exposure prophylaxis (PrEP) candidates is a challenge
in planning for the safe and effective roll‐out of this strategy. We explored the use of a …
in planning for the safe and effective roll‐out of this strategy. We explored the use of a …
[HTML][HTML] Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic
… Darrell Tan’s institution has received investigator-initiated research grants or in-… Darrell
Tan is a site principal investigator for clinical trials sponsored by GlaxoSmithKline. Darrell Tan is …
Tan is a site principal investigator for clinical trials sponsored by GlaxoSmithKline. Darrell Tan is …
Mpox in people with advanced HIV infection: a global case series
…, AF Costa, SQ Rocha, JV Madruga, DHS Tan… - The Lancet, 2023 - thelancet.com
Background People living with HIV have accounted for 38–50% of those affected in the 2022
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …
multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell …
[HTML][HTML] Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
…, J Powis, J McCready, DHS Tan… - The Lancet …, 2021 - thelancet.com
Background To date, only monoclonal antibodies have been shown to be effective for
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral …
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral …
[HTML][HTML] Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial
Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …
remains ill defined in a global context. The World Health Organization Solidarity randomized …
[HTML][HTML] Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
… Darrell Tan and Mark Hull wrote the first draft of the synopsis. All of the authors revised the
manuscript critically for important intellectual content, gave final approval of the version to be …
manuscript critically for important intellectual content, gave final approval of the version to be …
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including stigma, …
challenges associated with daily oral HIV treatment in people living with HIV, including stigma, …
